

TO: Mail Stop 8
 Director of the U.S. Patent and Trademark Office
 P.O. Box 1450
 Alexandria, VA 22313-1450

**REPORT ON THE
 FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK**

AUG 24 2007

U.S. PATENT & TRADEMARK OFFICE

In Compliance with 35 § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been

filed in the U.S. District Court for the District of Maryland on the following Patents or Trademarks:


DOCKET NO.	DATE FILED	U.S. DISTRICT COURT FOR THE DISTRICT OF MARYLAND
AW-02-1135		
PLAINTIFF	DEFENDANT	
MedImmune, Inc.	Centocor, Inc., et al	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,807,715		
2		
3		
4		
5		

In the above—entitled case, the following patent(s) have been included:

DATE INCLUDED	INCLUDED BY	<input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT
See attached

CLERK	(BY) DEPUTY CLERK	DATE
Felicia C. Cannon		8/22/07

Copy 1—Upon initiation of action, mail this copy to Commissioner Copy 3—Upon termination of action, mail this copy to Commissioner
 Copy 2—Upon filing document adding patent(s), mail this copy to Commissioner Copy 4—Case file copy

~~FILED~~
~~LODGED~~
**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MARYLAND**

AUG 22 2007

ENTERED
RECEIVED

MEDIMMUNE, INC.,

:

AT GREENBELT
CLERK U.S. DISTRICT COURT
DISTRICT OF MARYLAND
BY DEPUTY

Plaintiff

:

v.

:

Civil Action No.: AW-02-CV-1135

CENTOCOR, INC., et al.,

:

Defendants

:

...ooOoo...

ORDER

This matter having come before the Court on a Motion for Voluntary Dismissal filed by Plaintiff MedImmune, Inc. ("MedImmune") pursuant to Rule 41(a)(2) of the Federal Rules of Civil Procedure, and this Court having considered the matter and being sufficiently advised, IT IS ORDERED, ADJUDGED AND DECREED THAT:

1. The Court has specific personal jurisdiction over the parties for purposes of this action only.


2. MedImmune's claims against Defendants Centocor, Inc. ("Centocor"), The Trustees of Columbia University in the City of New York ("Columbia") and The Board of Trustees of the Leland Stanford Junior University ("Stanford") (together with Columbia, the "Universities") in the above-captioned action are hereby dismissed with prejudice; and

3. In the event that an infringement action under U.S. Patent No. 5,807,715 (the '715 Patent) is brought against MedImmune or an affiliate of MedImmune with respect to an immunoglobulin that at no time in the past or future was or is licensed under the '715 Patent, MedImmune or its affiliate shall have the right to defend such

action on the basis that such immunoglobulin does not infringe and/or that the '715 Patent is invalid and/or unenforceable, except that MedImmune shall not have the right to assert a defense of invalidity or unenforceability in-defense of an infringement action under the '715 patent with respect to any of the immunoglobulins of Exhibit I attached hereto or immunologically functional fragments thereof.

4. Each side is to bear its own costs and attorneys' fees in connection with the above-captioned action.

SO ORDERED this 22nd day of August, 2007.



HON. ALEXANDER WILLIAMS
United States District Judge

EXHIBIT I

Immunoglobulins against any of the following:

Respiratory Syncytial Virus (RSV) (Except for Numax and Synagis)

Human Metapneumovirus (hMPV)

Staphylococcus epidermidis

Staphylococcus aureus

Candida albicans

Interleukin-9 (IL-9)

Interleukin-5 Receptor (IL-5R)

Interleukin-6 (IL-6)

Interferon alpha (IFN α)

Interferon alpha Receptor (IFN α R)

CD19

CD20

CD22

High Mobility Group Box 1 (HMGB1)

YKL40

Acidic Mammalian Chitinase (AMCase)

Chitotriosidase

Inducible co-stimulator (ICOS)

Receptor for Advanced Glycosylation End products (RAGE)

C5a

CD2

EphA2

EphA4

EphB4

Ephrin B2

Anaplastic Lymphoma Kinase (ALK)

$\alpha_v\beta_3$